Raymond James Downgrades BridgeBio Pharma to Market Perform

Benzinga Newsdesk www.benzinga.com Negative 94.4%

Neg 94.4% Neu 0% Pos 0%

Raymond James analyst Martin Auster downgrades BridgeBio Pharma (NASDAQ:BBIO) from Outperform to Market Perform.

Comments

No comments yet. Be the first!